<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /> 结论:1,本研究再次证明了脓毒症病人存在免疫抑制状态,用CD14+单核细胞HLA-DR<30%进行判断并指导进行特异性的免疫增强治疗是安全和可靠的;2,再次证明CD14+单核细胞HLA-DR表达对评估脓毒症病人预后具有重要价值;3,首次将TP-5用于脓毒症免疫抑制治疗,并初步显示对于逆转免疫抑制可能是有效的,但由于缺乏对照治疗目前暂不能获确切结论,亟需要设计更严格的研究给予确认;4,本研究发现脓毒症免疫抑制发生的机制与炎性细胞因子的平衡并无直接关系,提示CARS假说可能存在严重缺陷。 参考文献 1,Bone RC. Sir Isaac Newton,sepsis,SIRS,and CARS. Crit Care Med,1996,24:1125-8 2,HD. Volk,P. Reinke,D. Krausch. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med,1996,22: 1-8 3,American College of Chest Physiicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physiicians/Society of Critical Care Medicine Consensus Conference. Difinitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med,1982,20:864-74 4,Bone RC. Why Sepsis Trials Fail. JAMA,1996,276:565-6 5,Bone RC. Immunologic Dissonance: A Continuing Evolution in Our Understanding of the Systemic Inflammatory Response Syndrome (SIRS) and the Multiple Organ Dysfunction Syndrome. Annals of Internal Med,1996,125:680-7 6,胸腺五肽医生手册 海南中和药业有限公司 7,JC. Marshall. Clinical trials of mediator-directed therapy in sepsis: what have we learned. Intensive Care Med,2000,26 (suppl): S75-S83 8,Panacek EA,Marshall J,Fischkoff S,et al. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: Results of the MONARCS trial. Abstr,Chest,2000,118 (suppl):88S 9,Reinhart k,Menges T,Gardlund B,et al. Randomized,placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med,2001,29:765-9 10,Melhus O,Nick G A,Edward D B,et al. Effect of TNF alpha. J Leuka Biol,1994,49:21 |